Anticoagulation in patients with non-valvular atrial fibrillation: An evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population

Current Medical Research and Opinion

Volumn 21, Issue 12, 2005, Pages 1905-1913

  Currie, Craig J ^a,b,e   McEwan, Phil ^a,b   Emmas, Cathy ^c   Morgan, Christopher Ll ^a   Peters, John R ^d  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Cardiff Research Consortium Limited   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d LLANDOUGH HOSPITAL   (United Kingdom)

^e Cardiff Research Consortium   (United Kingdom)

Author keywords

Anticoagulation; Mortality; Population study; Stability; Warfarin

Indexed keywords

WARFARIN;

ADULT; AGED; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLEEDING TENDENCY; CONTROLLED STUDY; DISEASE ASSOCIATION; EVALUATION; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HEART ATRIUM FIBRILLATION; HOSPITAL PATIENT; HUMAN; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREDICTION; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; ROC CURVE; SURVIVAL ANALYSIS; WARFARIN;

EID: 29144532619     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X75050     Document Type: Article

References (47)

1. Ansell JE, Buttaro ML, Thomas OV, Knowlton CH. Consensus guidelines for coordinating outpatient oral anticoagulation therapy management [Anticoagulation Guidelines Task Force]. Ann Pharmacother 1997;31:604-15
2. Lane DA, Lip GY. Anticoagulation as thromboprophylaxis for atrial fibrillation: implications in the 'real world' and the need for risk stratification. Blood Coagul Fibrinolysis 2005;16:461-4
3. Brophy MT, Synder KE, Gaehde S, et al. Anticoagulation use for atrial fibrillation in the elderly. J Am Geriatr Soc 2004;52:1151-6
4. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high risk patients with atrial fibrillation: stroke prevention in atrial fibrillation randomized clinical trial. Lancet 1996;348:633-8
5. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to anticoagulation therapy. J Am Coll Cardiol 2003;41:1633-52
6. Gullov AL, Koefoed BG, Petersen P et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998;158:1513-21
7. Feinberg WM, Blackshear JL, Laupacis A, et al. The prevalence of atrial fibrillation. Analysis and implications. Arch Int Med 1995;155:469-73
8. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
9. Moulton AW, Singer DE, Hass JS. Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case control study. Am J Med 1991;91:156-61
10. Davies RC, Hobbs FDR, Kenkre JE, et al. Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study. Br Med J 2002;325:1156-61
11. Fitzmaurice DA, Machin SJ. Recommendations for patients undertaking self management of oral anticoagulation. Br Med J 2001;323:985-9
12. Chatap G, Giraud K, Vincent JP. Atrial fibrillation in the elderly: facts and management. Drugs Aging 2002;19:819-46
13. Morgan S, Mant D. Randomised trials of two approaches to screening for atrial fibrillation in UK general practice. Br J Gen Pract 2002;52:373-80
14. Sommerville S, Sommerville J, Croft P, Lewis M. Atrial fibrillation: a comparison of methods to identify cases in general practice. Br J Gen Pract 2000;50:727-9
15. Wheeldon NM, Tayler DI, Anagnostou E, et al. Screening for atrial fibrillation in primary care. Heart 1998;79:50-5
16. Department of Health. National framework for older people. Standard 5; stroke. London: Stationery Office; 2001
17. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke [EAFT (European Atrial Fibrillation Trial) Study Group]. Lancet 1992;342:1255-62
18. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomised controlled trials. Arch Int Med 1994;154:1449-57
19. van Walraven C, Gart RG, Singer DE, et al. Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation. An individual patient meta-analysis. J Am Med Assoc 2002;288:2441-8
20. van der Meer FJ, Rosendaal FR, Andenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy. Arch Int Med 1993;153:1557-62
21. Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics and drug interactions. Semin Vasc Med 2003;3:221-30
22. Kirchheiner JA, Ufer MB, Walter EC, et al. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics 2004;14:19-26
23. Franco V, Carisi AP, Clausell N, Rhode LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med 2004;116:651-6
24. Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. Ann Int Med 1998;120:897-902
25. Chow WH, Chow TC, Tse TM, et al. Anticoagulation instability with life-threatening complications after dietary modification. Postgrad Med J 1990;66:855-7
26. Wells PS, Holbrook AM, Crowther RN, Hirsch J. Ann Int Med 1994;121:676-83
27. Kalra PA, Cooklin M, Wood G, et al. Dietary modification as a cause of anticoagulation instability. Lancet 1988;2:803
28. Sudlow M, Rodgers H, Kenny RA, Thompson R. Population based study of use of anticoagulants among patients with atrial fibrillation in the community. Br Med J 1997;314:1529-30
29. Olsson SB; Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;22:1691-8
30. Poller I, Wright D, Rowland M. Prospective comparative study of computer programmes used for management of warfarin. J Clin Pathol 1993;46:781
31. Poller L, Shiach CR, Maccallum PK, et al. Multicentre randomised study of computerised anticoagulant dosage [European Concerted Action on Anticoagulation]. Lancet 1998;352:1505-9
32. Gill L, Goldacre M, Simmons H, et al. Computerised linking of medical records: methodological guidelines. J Epidemiol Community Health 1993;47:316-9
33. Jones M, McEwan P, Morgan CLl, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvular atrial fibrillation: a record linkage study in a large British population. Heart 2005;91:472-77
34. Currie CJ, Jones M, Goodfellow J, et al. Evaluation of survival and ischaemic and thromboembolic event rates in patients with nonvalvular atrial fibrillation in the general population when treated and untreated with warfarin. Heart 2005 [doi:10.1136/hrt.2004.058339]
35. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-9
36. Azar AJ, Deckers JW, Rosendaal FR, et al. Assessment of therapeutic control in a long-term anticoagulant trial in post-myocardial infarction patients. Thromb Haemost 1993;72:347-75
37. Hosmer DW, Lemeshaw S. Applied logistic regression, 2nd ed. New York: Wiley Series in Probability and Statistics; 2000
38. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43
39. Obuchowski NA. Nonparametric analysis of clustered ROC curve analysis. Biometrics 1997;53:567-78
40. Yasaka M, Yamaguchi T. Secondary prevention of stroke in patients with nonvalvular atrial fibrillation: optimal intensity of anticoagulation. CNS Drugs 2001;15:623-31
41. Atwood JE, Albers GW. Anticoagulation and atrial fibrillation. Herz 1993;18:27-38
42. Green ES, Bond S, Rhodes S, et al. Bleeding complications of oral anticoagultant therapy: a prospective audit. Br J Haematol 2005;34(Suppl 1):11
43. Benjamin E, Wolf P, D'Agostino R, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52
44. Ezekowitz M, Levine J. Preventing stroke in patients with atrial fibrillation. J Am Med Assoc 1999;281:1183-835
45. Shapiro DE. The interpretation of diagnostic tests. Stats Methods Med Res 1999;8:113-34
46. Stewart S, Murphy N, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-92
47. Parry D, Fitzmaurice D, Raftery J. Anticoagulation management in primary care: a trial-based economic evaluation. Br J Haematol 2000;111:530-3